Guideline Summary: Cetirizine vs. Diphenhydramine – Evidence‑Based Recommendations

Safety in Infants and Children

• Cetirizine has been studied safely for continuous use in infants up to 18 months of age (no specific adverse safety signals reported) 1.

Sedation Profile

• Cetirizine produces sedation in approximately 13.7 % of patients, compared with 6.3 % for placebo; this rate is markedly lower than that observed with diphenhydramine 1, 2.

Renal Impairment Dosing

• In moderate renal impairment, the cetirizine dose should be reduced to 5 mg once daily; it should be avoided in severe renal impairment (creatinine clearance < 10 mL/min) 1.

Elderly Patients (≥ 65 years)

• Older adults exhibit increased sensitivity to the sedative effects of both cetirizine and diphenhydramine 2.

Acute Anaphylaxis Management

• The allergy‑clinical‑immunology guideline recommends diphenhydramine 1–2 mg/kg (≈ 25–50 mg per dose) administered intravenously or intramuscularly as second‑line therapy after epinephrine 3, 4, 5, 6.

Switching Strategies

From Diphenhydramine to Cetirizine

• When converting, patients can expect a sedation incidence of about 13.7 % (still significantly lower than with diphenhydramine) 1, 2.
• If drowsiness occurs, evening dosing of cetirizine is advisable 2.
• For school‑age children, cetirizine is strongly preferred to avoid academic performance impairment associated with diphenhydramine‑induced sedation 2.

From Cetirizine to Diphenhydramine

• (Not a direct equivalency; dosing frequency must be increased to maintain continuous antihistamine coverage) – omitted because no cited source provides a specific conversion recommendation.